Real-world outcomes in patients with AML and MDS treated with Azacitidine

被引：0
|
作者：
Prusak, E. [1 ]
Lawes, M. [2 ]
Collins, A. [2 ]
机构：
[1] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England
[2] Norfolk & Norwich Univ Hosp, Haematol, Norwich, Norfolk, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
AML; Azacitidine; mds;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-PO-0
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [1] Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'
    Mozessohn, Lee
    Cheung, Matthew C.
    Mittmann, Nicole
    Earle, Craig C.
    Liu, Ning
    Buckstein, Rena
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1445 - 1454
  • [2] Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis
    Wisniewski, Kamil
    Pruszczyk-Matusiak, Katarzyna
    Pula, Bartosz
    Lech-Maranda, Ewa
    Gora-Tybor, Joanna
    CANCERS, 2024, 16 (07)
  • [3] Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience
    Braulke, Friederike
    Schweighofer, Adrian
    Schanz, Julie
    Shirneshan, Katayoon
    Ganster, Christina
    Pollock-Kopp, Beatrix
    Leha, Andreas
    Haase, Detlef
    LEUKEMIA RESEARCH, 2023, 124
  • [4] Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience
    Ozbalak, Murat
    Cetiner, Mustafa
    Bekoz, Huseyin
    Atesoglu, Elif Birtas
    Ar, Cem
    Salihoglu, Ayse
    Tuzuner, Nukhet
    Ferhanoglu, Burhan
    HEMATOLOGICAL ONCOLOGY, 2012, 30 (02) : 76 - 81
  • [5] Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares, Helena
    Arnan, Montserrat
    Sanchez-Ortega, Isabel
    Sureda, Anna
    Duarte, Rafael F.
    MYCOSES, 2016, 59 (08) : 516 - 519
  • [6] Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia
    Leber, Brian
    Ruiz, Marcia T.
    Elgendy, Hany
    Pettersson, Filippa
    Prebet, Thomas
    Vigil, Carlos E.
    Parikh, Rohan C.
    Korgaonkar, Siddhi
    Bello, Fareedat
    Davis, Keith L.
    Gaugler, Lona
    Strocchia, Maria
    Sieluk, Jan
    Li, Yeran
    Schuh, Andre C.
    CANCER, 2025, 131 (08)
  • [7] Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders
    Polgarova, Kamila
    Vargova, Karina
    Kulvait, Vojtech
    Dusilkova, Nina
    Minarik, Lubomir
    Zemanova, Zuzana
    Pesta, Michal
    Jonasova, Anna
    Stopka, Tomas
    ONCOTARGET, 2017, 8 (67) : 111966 - 111978
  • [8] Real-World Outcomes of Decitabine plus Venetoclax With IDH Inhibition for AML
    Kusiel, Justin
    Baratam, Praneeth
    Green, Kimberly
    Coltoff, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S297 - S297
  • [9] BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
    Cluzeau, Thomas
    Robert, Guillaume
    Mounier, Nicolas
    Karsenti, Jean Michel
    Dufies, Maeva
    Puissant, Alexandre
    Jacquel, Arnaud
    Renneville, Aline
    Preudhomme, Claude
    Cassuto, Jill Patrice
    Raynaud, Sophie
    Luciano, Frederic
    Auberger, Patrick
    ONCOTARGET, 2012, 3 (04) : 490 - 501
  • [10] Real-world study of the use of azacitidine in myelodysplasia in Australia
    Enjeti, Anoop
    Ashraf, Asma
    Caillet, Vincent
    Alam, Arif
    Silar, Jonathan
    Keer, Harold
    Castaldi, Francesco
    Paine, Taleisha
    EJHAEM, 2024, 5 (03): : 527 - 534
12345